Aviso Financial Inc. Increases Stock Holdings in Cencora, Inc. $COR

Key Points

• Aviso Financial Inc. increased its stake in Cencora, Inc. by 17.5%, acquiring an additional 1,305 shares, bringing its total holdings to 8,769 shares valued at approximately $2.44 million.
• Insider selling activity included CEO Robert P. Mauch selling nearly 5,000 shares, representing a 10.50% decrease in his ownership, and Chairman Steven H. Collis selling over 14,500 shares, resulting in a 4.47% decrease in his ownership.
• Cencora reported quarterly earnings of $4.00 per share, exceeding analyst expectations by $0.21, with revenue of $80.66 billion, up 8.7% year-over-year.

Aviso Financial Inc. raised its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 17.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,769 shares of the company's stock after acquiring an additional 1,305 shares during the quarter. Aviso Financial Inc.'s holdings in Cencora were worth $2,439,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Price T Rowe Associates Inc. MD boosted its position in shares of Cencora by 0.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,859,452 shares of the company's stock worth $1,990,542,000 after acquiring an additional 78,066 shares in the last quarter. Boston Partners boosted its position in shares of Cencora by 8.1% during the 1st quarter. Boston Partners now owns 5,411,193 shares of the company's stock worth $1,505,984,000 after acquiring an additional 404,093 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Cencora by 62.3% during the 4th quarter. Bank of America Corp DE now owns 5,193,807 shares of the company's stock worth $1,166,944,000 after acquiring an additional 1,994,256 shares in the last quarter. Invesco Ltd. boosted its position in shares of Cencora by 42.1% during the 1st quarter. Invesco Ltd. now owns 4,607,964 shares of the company's stock worth $1,281,429,000 after acquiring an additional 1,364,433 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of Cencora by 11.6% during the 4th quarter. Northern Trust Corp now owns 2,421,237 shares of the company's stock worth $544,004,000 after acquiring an additional 252,028 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

COR has been the subject of a number of research analyst reports. Robert W. Baird upped their target price on Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. Citigroup upped their target price on Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Wells Fargo & Company upped their target price on Cencora from $337.00 to $354.00 and gave the company an "overweight" rating in a research report on Wednesday, August 13th. Morgan Stanley set a $330.00 target price on Cencora and gave the company an "equal weight" rating in a research report on Wednesday, July 16th. Finally, UBS Group upped their target price on Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $311.25.

Cencora Stock Performance

Cencora stock traded down $10.9810 during mid-day trading on Friday, reaching $292.2490. 1,706,519 shares of the company were exchanged, compared to its average volume of 1,331,423. Cencora, Inc. has a twelve month low of $218.65 and a twelve month high of $309.35. The firm's 50-day simple moving average is $293.48 and its two-hundred day simple moving average is $280.44. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. The firm has a market cap of $56.66 billion, a PE ratio of 30.07, a price-to-earnings-growth ratio of 1.44 and a beta of 0.58.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, topping analysts' consensus estimates of $3.79 by $0.21. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company had revenue of $80.66 billion during the quarter, compared to analysts' expectations of $80.34 billion. During the same period last year, the firm earned $3.34 EPS. The firm's revenue for the quarter was up 8.7% on a year-over-year basis. Equities analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, August 15th will be issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Friday, August 15th. Cencora's dividend payout ratio is 22.63%.

Insiders Place Their Bets

In other Cencora news, CEO Robert P. Mauch sold 4,968 shares of the stock in a transaction on Friday, July 18th. The stock was sold at an average price of $294.11, for a total transaction of $1,461,138.48. Following the sale, the chief executive officer owned 42,351 shares in the company, valued at approximately $12,455,852.61. This represents a 10.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Steven H. Collis sold 14,578 shares of the stock in a transaction on Tuesday, July 22nd. The shares were sold at an average price of $292.67, for a total value of $4,266,543.26. Following the sale, the chairman owned 309,913 shares in the company, valued at approximately $90,702,237.71. This trade represents a 4.49% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 34,125 shares of company stock worth $9,993,789. 10.80% of the stock is owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.